OVID: Ovid Therapeutics, Inc.
About
Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.
Current Value
$1.021 Year Return
Current Value
$1.021 Year Return
Key Details
Market Cap
$73.14M
P/E Ratio
-2.24
1Y Stock Return
-68.60%
1Y Revenue Growth
113.07%
Dividend Yield
0.00%
Price to Book
1.0
Strategies that include OVID
Stock's related to OVID
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| AMCX | 46.02% | $396.64M | -43.07% | 0.00% |
| INNV | 37.11% | $647.47M | -9.13% | 0.00% |
| SYRE | 31.25% | $1.38B | +169.81% | 0.00% |
| GRAL | 31.08% | $459.22M | -13.00% | 0.00% |
| SPCE | 29.97% | $196.64M | -84.01% | 0.00% |
| CARM | 29.63% | $36.20M | -64.46% | 0.00% |
| SAGE | 28.83% | $300.36M | -74.61% | 0.00% |
| AEHR | 28.81% | $330.68M | -56.08% | 0.00% |
| ARCT | 28.71% | $489.20M | -21.27% | 0.00% |
| CHGG | 27.66% | $175.24M | -83.42% | 0.00% |
| MRCY | 26.57% | $2.32B | +13.35% | 0.00% |
| ABCL | 26.44% | $800.44M | -37.56% | 0.00% |
| RYTM | 26.43% | $3.69B | +79.50% | 0.00% |
| GILT | 26.37% | $310.17M | -13.38% | 0.00% |
| LPX | 26.28% | $7.84B | +85.45% | 0.70% |
| ETON | 26.27% | $271.28M | +195.77% | 0.00% |
| INTA | 25.99% | $4.48B | +52.18% | 0.00% |
| RCUS | 25.98% | $1.33B | +5.07% | 0.00% |
| BHR | 25.96% | $222.85M | +58.02% | 6.01% |
| AMWD | 25.89% | $1.46B | +29.41% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| TRMD | -0.05% | $2.31B | -24.74% | 25.24% |
| CAG | -0.07% | $12.64B | -6.10% | 5.26% |
| E | 0.09% | $46.24B | -10.80% | 9.02% |
| SPR | -0.09% | $3.72B | +23.27% | 0.00% |
| QNTM | 0.09% | $9.19M | -94.36% | 0.00% |
| LPLA | 0.10% | $23.55B | +38.13% | 0.38% |
| CREG | 0.11% | $6.14M | -35.78% | 0.00% |
| MESO | -0.12% | $1.23B | +347.11% | 0.00% |
| JNPR | 0.15% | $11.61B | +30.55% | 2.49% |
| CATO | 0.15% | $127.11M | -9.52% | 11.00% |
| WWD | -0.16% | $10.19B | +29.97% | 0.44% |
| TPB | 0.20% | $1.08B | +167.44% | 0.45% |
| TTE | -0.20% | $138.45B | -11.95% | 5.50% |
| GE | -0.23% | $192.17B | +85.70% | 0.52% |
| TECX | -0.23% | $602.80M | +170.24% | 0.00% |
| PZZA | 0.25% | $1.54B | -28.47% | 3.91% |
| BILI | 0.25% | $6.14B | +30.79% | 0.00% |
| GL | -0.26% | $9.18B | -8.60% | 0.86% |
| TS | -0.27% | $20.74B | +8.26% | 4.72% |
| PRPH | -0.28% | $18.14M | -82.61% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| XPOF | -21.89% | $504.00M | +11.50% | 0.00% |
| MCK | -15.00% | $78.15B | +35.51% | 0.42% |
| VHC | -13.41% | $19.06M | -38.36% | 0.00% |
| KVUE | -12.32% | $45.42B | +19.05% | 3.43% |
| KNOP | -12.28% | $210.40M | +11.75% | 1.68% |
| SUN | -10.15% | $7.32B | +1.51% | 6.47% |
| STZ | -10.13% | $43.65B | +2.63% | 1.64% |
| OXBR | -9.94% | $19.05M | +178.18% | 0.00% |
| NGL | -9.85% | $572.94M | +5.60% | 0.00% |
| ORLY | -9.84% | $69.31B | +22.06% | 0.00% |
| COR | -9.52% | $47.48B | +21.20% | 0.86% |
| CYD | -9.24% | $364.46M | -2.94% | 4.26% |
| CBOE | -8.72% | $21.46B | +15.84% | 1.11% |
| NOC | -8.65% | $71.54B | +4.23% | 1.60% |
| WRB | -8.42% | $22.94B | +29.98% | 0.69% |
| KDP | -8.28% | $42.76B | -1.22% | 2.77% |
| ACGL | -8.13% | $36.00B | +16.84% | 0.00% |
| MNST | -8.08% | $52.25B | -1.95% | 0.00% |
| PULM | -7.97% | $19.83M | +202.98% | 0.00% |
| AZO | -7.87% | $52.52B | +16.10% | 0.00% |
ETF's related to OVID
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| RSPA | 43.53% | $273.87M | 0% |
| EFAA | 39.38% | $117.38M | 0% |
| QQA | 35.79% | $135.01M | 0% |
| XBI | 32.07% | $6.58B | 0.35% |
| ARKG | 32.06% | $1.13B | 0.75% |
| IBB | 31.56% | $6.66B | 0.45% |
| GNOM | 31.25% | $70.59M | 0.5% |
| PTH | 31.20% | $143.31M | 0.6% |
| XPH | 30.83% | $157.87M | 0.35% |
| IWC | 30.65% | $933.99M | 0.6% |
| PBE | 27.81% | $258.53M | 0.58% |
| PINK | 27.54% | $161.15M | 0.5% |
| FBT | 27.50% | $1.11B | 0.56% |
| IFV | 27.38% | $178.46M | 1.03% |
| FYX | 27.28% | $959.00M | 0.6% |
| PRNT | 27.00% | $95.35M | 0.66% |
| NUSC | 26.99% | $1.27B | 0.31% |
| VTWO | 26.90% | $12.38B | 0.1% |
| ESML | 26.76% | $1.90B | 0.17% |
| IWM | 26.58% | $75.73B | 0.19% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| FLOT | -0.04% | $7.31B | 0.15% |
| CSHI | -0.30% | $482.85M | 0.38% |
| DBMF | 0.39% | $1.02B | 0.85% |
| IYK | 0.52% | $1.30B | 0.4% |
| GBIL | 0.56% | $5.60B | 0.12% |
| FLTR | -0.60% | $1.79B | 0.14% |
| TBIL | -0.61% | $4.38B | 0.15% |
| SHYD | 0.63% | $311.50M | 0.35% |
| PDBC | 0.73% | $4.40B | 0.59% |
| HDRO | -0.76% | $164.26M | 0.3% |
| BILZ | -0.85% | $563.02M | 0.14% |
| GSG | -0.88% | $914.42M | 0.75% |
| DBC | 0.88% | $1.39B | 0.87% |
| SEIX | -0.94% | $268.81M | 0.62% |
| JUCY | 1.11% | $324.29M | 0.6% |
| JBBB | -1.12% | $1.26B | 0.49% |
| IAK | 1.15% | $760.79M | 0.39% |
| COMT | -1.31% | $829.06M | 0.48% |
| BTF | 1.37% | $51.69M | 1.24% |
| KLIP | 1.52% | $125.85M | 0.93% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -21.47% | $388.04M | 1.43% |
| VIXY | -12.71% | $195.31M | 0.85% |
| MINT | -12.39% | $11.62B | 0.35% |
| EQLS | -11.30% | $76.08M | 1% |
| USDU | -8.53% | $201.97M | 0.5% |
| CTA | -7.33% | $350.27M | 0.78% |
| KMLM | -6.39% | $353.87M | 0.9% |
| AGZD | -6.32% | $142.76M | 0.23% |
| DUSB | -5.97% | $797.63M | 0.15% |
| IBDP | -5.86% | $2.11B | 0.1% |
| CCOR | -5.70% | $109.04M | 1.18% |
| KCCA | -5.70% | $220.51M | 0.87% |
| KRBN | -4.87% | $242.47M | 0.85% |
| UUP | -4.79% | $309.25M | 0.77% |
| DBO | -3.73% | $217.57M | 0.77% |
| DBE | -3.53% | $50.13M | 0.77% |
| CLOI | -2.75% | $715.40M | 0.4% |
| TBLL | -2.74% | $1.92B | 0.08% |
| FLRN | -2.50% | $2.33B | 0.15% |
| TAIL | -2.46% | $67.98M | 0.59% |
News
Yahoo
Ovid Therapeutics (OVID) delivered earnings and revenue surprises of -5.26% and 15.33%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
A Phase 1 SAD/MAD study of OV329 is progressing as planned, and based on encouraging human safety data to date, Ovid will engage regulators about adding cohorts to increase potential dosing opportunities for Phase 2 programs.A regulatory application for a Phase 1 trial of OV350, the first candidate from Ovid's KCC2 direct activator library, is expected to be filed in Q4 2024.The Company will host a KCC2 Download Day on November 13 to provide updates on Ovid's platform of KCC2 direct activators a
Finnhub
Ovid Therapeutics Corporate Presentation November 2024 © Copyright 2024 Ovid Therapeutics ...
Yahoo
As the U.S. stock market continues to rally post-election, with major indices like the S&P 500 and Nasdaq reaching record highs, investors are exploring various opportunities in different corners of the market. Penny stocks, often associated with smaller or newer companies, remain a relevant investment area despite their somewhat outdated moniker. These stocks can offer potential for growth at lower price points when backed by strong financials and fundamentals, presenting intriguing...
Yahoo
KCC2 Download Day on Wednesday, November 13, 2024NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced that it will host an investor event focused on its portfolio of direct potassium chloride co-transporter 2 (KCC2) activators on Wednesday, November 13, 2024. The event will take place at Ovid’s headquarters in New York’s Hudson Yar
Yahoo
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.